Retinopathy in subjects with impaired fasting glucose: The NANSY-Eye baseline report

Diabetes, Obesity and Metabolism

Volumn 10, Issue 8, 2008, Pages 646-651

  Tyrberg, Maria ^a   Melander, A ^b,c   Lovestam Adrian M ^d   Lindblad, U ^b,c,e  

^a HELSINGBORG HOSPITAL   (Sweden)

^b Department of Clinical Sciences ^*  (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Network for Pharmacoepidemiology Foundation   (Sweden)

^e Skaraborgs Institutet   (Sweden)

Author keywords

Clinical trial; Hypertension; Impaired fasting glucose; Retinopathy; Sulphonylurea

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 47949104275     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00759.x     Document Type: Article

References (36)

1. Trautner C, Icks A, Haastert B, Plum F, Berger M. Incidence of blindness in relation to diabetes. A population-based study. Diabetes Care 1997; 20: 1147-1153.
2. Giusti C. Retinopathy in juvenile diabetes: A 10-year (1990-2000) review. Pediatr Diabetes 2001; 2: 83-93.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
4. World Health Organisation. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation. Part 1; Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organisation, 1999.
5. Unwin N, Shaw J, Zimmet P, Alberti K. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet Med 2002; 19: 708-723.
6. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
7. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. UKPDS 6. Diabetes Res 1990; 13: 1-11.
8. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. Diabet Med 1997; 14: 449-456.
9. van Leiden HA, Dekker JM, Moll AC et al. Blood pressure, lipids, and obesity are associated with retinopathy: The Hoorn Study. Diabetes Care 2002; 25: 1320-1325.
10. Lindblad U, Lindwall K, Sjöstrand Å, Ranstam J, Melander A. The NEPI Antidiabetes Study (NANSY). 1: Short-term dose-effect relations of glimeperide in subjects with impaired fasting glucose. Diabetes Obes Metab 2001; 3: 443-451.
11. Hannestad U, Lundblad A. Accurate and precise isotope dilution mass spectrometry method for determining glucose in whole blood. Clin Chem 1997; 43: 794-800.
12. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy. The EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 437-444.
13. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243.
14. Rastam L, Sjonell GA. New device for measuring blood pressure in adults. Lancet 1991; 337: 249-250.
15. Guidelines sub-committee guidelines for management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-918.
16. Eckerbom S, Bergqvist Y, Jeppsson JO. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994; 31: 355-360.
17. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578-582.
18. Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C. Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 1993; 39: 2146-2150.
19. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population. Clin Chem 2000; 46: 934-938.
20. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565: 441-446.
21. van Leiden HA, Dekker JM, Moll AC et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population. Arch Ophthalmol 2003; 121: 245-251.
22. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia 1999; 42: 1107-1112.
23. Wong TY, Klein R, Sharett AR et al. Retinal arteriolar narrowing and risk of diabetes in middle-aged persons. The Arteriosclerosis Risk in Community Study. JAMA 2002; 287: 2528-2533.
24. Porta M, Grosso A, Veglio F. Hypertensive retinopathy that is more than meets the eye. J Hypertens 2005; 23: 683-696.
25. Wong T, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351: 2310-2317.
26. Kohner EM, Patel V, Rassam SMB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44: 603-607.
27. Prospective Diabetes Study UK (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-713.
28. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risk of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus UKPDS 69. Arch Ophthalmol 2004; 122: 1631-1640.
29. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
30. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
31. Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.
32. van Hecke MV, Dekker JM, Nijpels G et al. Inflammation and endothelial dysfunction are associated with retinopathy: The Hoorn Study. Diabetologia 2005; 48: 1300-1306.
33. Henricsson M, Karlsson C, Ekholm L et al. Colour slides or digital photography in diabetes screening - a comparison. Acta Ophthalmol Scand 2000; 78: 164-168.
34. Palmowski AM, Sutter EE, Bearse MA Jr, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci 1997; 38: 2586-2596.
35. Tyrberg M, Ponjavic V, Lövestam Adrian M. Multifocal electroretinography (mfERG) in insulin dependent diabetics with and without clinically apparent retinopathy. Doc Ophthalmol 2005; 110: 137-143.
36. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edn. Boston: Little Brown, 1994.